ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Despite the significant clinical success of BCR-ABL tyrosine kinase inhibitors (TKIs) in the treatment of CML, mechanisms of TKI-resistance have evolved resulting in CML remaining one of the most difficult types of cancer to treat (61).